TY - JOUR
T1 - Relationships of p16 immunohistochemistry and other biomarkers with diagnoses of cervical abnormalities implications for LAST terminology
AU - Castle, Philip E.
AU - Adcock, Rachael
AU - Cuzick, Jack
AU - Wentzensen, Nicolas
AU - Torrez-Martinez, Norah E.
AU - Torres, Salina M.
AU - Stoler, Mark H.
AU - Ronnett, Brigitte M.
AU - Joste, Nancy E.
AU - Darragh, Teresa M.
AU - Gravitt, Patti E.
AU - Schiffman, Mark
AU - Hunt, William C.
AU - Kinney, Walter K.
AU - Wheeler, Cosette M.
N1 - Funding Information:
Information reported in this publication was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the US National Institutes of Health under award number U19AI113187 and through its Developmental Research Pilot (DRP) program. Roche Molecular Systems and Ventana, a Roche Company, provided reagents and equipment at no cost.
Funding Information:
PEC has received HPV tests and assays for research at a reduced or no cost from Roche, Cepheid, Becton Dickinson, and Arbor Vita Corporation. JC has received funds from grants, cooperative agreements, or subcontracts related to cervical screening and triage through his institution. JC reports grants and personal fees from Qiagen, grants from Hologic, grants and personal fees from Becton Dickinson, grants and personal fees from Genera Biosystems, grants from Gene First, and grants from Trovagene, outside the submitted work. NW is an employee of the National Cancer Institute, which has received HPV tests at reduced cost from BD and Roche. MHS is a consultant and has received fees for clinical trial development and as an expert pathologist in clinical trials for Merck, Roche/Ventana Medical Systems, Becton Dickinson (BD), Hologic/Gen Probe, Cepheid, and Inovio Pharmaceuticals and was Co-Lead of Work Group 4 and an author of the College of American Pathologists (CAP)–American Society of Colposcopy and Cervical Pathology (ASCCP) LAST Project. BMR received consulting fees from Merck as a member of pathology adjudication panel for HPV vaccine trials. TMD has received consultant fees from BD, Roche, Antiva, and Thevax; research supplies for anal cytology from Hologic; and was lead author on the CAP-ASCCP LAST Project. CMW has received funds from grants and cooperative agreements related to cervical screening and triage through her institution. CMW reports receiving reagents for HPV genotyping from Roche and reagents and equipment from Roche/Ventana Medical Systems through her institution and outside of the submitted work, personal fees from BD. The other authors have no relevant financial interest in the products or companies described in this article.
PY - 2020/6
Y1 - 2020/6
N2 - Context.-Lower Anogenital Squamous Terminology (LAST) standardization recommended p16INK4aimmunohistochemistry (p16 IHC) for biopsies diagnosed morphologically as cervical intraepithelial neoplasia (CIN) grade 2 (CIN2) to classify them as low-grade or high-grade squamous intraepithelial lesions (HSILs). Objective.-To describe the relationships of p16 IHC and other biomarkers associated with cervical cancer risk with biopsy diagnoses. Design.-A statewide, stratified sample of cervical biopsies diagnosed by community pathologists (CPs), including 1512 CIN2, underwent a consensus, expert pathologist panel (EP) review (without p16 IHC results), p16 IHC interpretation by a third pathology group, and human papillomavirus (HPV) genotyping, results of which were grouped hierarchically according to cancer risk. Antecedent cytologic interpretations were also available. Results.-Biopsies were more likely to test p16 IHC positive with increasing severity of CP diagnoses, overall (Ptrend ≤.001) and within each HPV risk group (Ptrend ≤.001 except for low-risk HPV [Ptrend <.010]). All abnormal grades of CP-diagnosed biopsies were more likely to test p16 IHC positive with a higher HPV risk group (Ptrend <.001), and testing p16 IHC positive was associated with higher HPV risk group than testing p16 IHC negative for each grade of CP-diagnosed biopsies (P <.001). p16 IHC-positive, CP-diagnosed CIN2 biopsies were less likely than CP-diagnosed CIN3 biopsies to test HPV16 positive, have an antecedent HSIL+cytology, or to be diagnosed as CIN3+by the EP (P,.001 for all). p16 IHC-positive, CP-diagnosed CIN1 biopsies had lower HPV risk groups than p16 IHC-negative, CP-diagnosed CIN2 biopsies (P,.001). Conclusions.-p16 IHC-positive, CP-diagnosed CIN2 appears to be lower cancer risk than CP-diagnosed CIN3. LAST classification of "HSIL" diagnosis, which includes p16 IHC-positive CIN2, should annotate the morphologic diagnosis (CIN2 or CIN3) to inform all management decisions, which is especially important for young (<30 years) women diagnosed with CIN2 for whom surveillance rather than treatment is recommended.
AB - Context.-Lower Anogenital Squamous Terminology (LAST) standardization recommended p16INK4aimmunohistochemistry (p16 IHC) for biopsies diagnosed morphologically as cervical intraepithelial neoplasia (CIN) grade 2 (CIN2) to classify them as low-grade or high-grade squamous intraepithelial lesions (HSILs). Objective.-To describe the relationships of p16 IHC and other biomarkers associated with cervical cancer risk with biopsy diagnoses. Design.-A statewide, stratified sample of cervical biopsies diagnosed by community pathologists (CPs), including 1512 CIN2, underwent a consensus, expert pathologist panel (EP) review (without p16 IHC results), p16 IHC interpretation by a third pathology group, and human papillomavirus (HPV) genotyping, results of which were grouped hierarchically according to cancer risk. Antecedent cytologic interpretations were also available. Results.-Biopsies were more likely to test p16 IHC positive with increasing severity of CP diagnoses, overall (Ptrend ≤.001) and within each HPV risk group (Ptrend ≤.001 except for low-risk HPV [Ptrend <.010]). All abnormal grades of CP-diagnosed biopsies were more likely to test p16 IHC positive with a higher HPV risk group (Ptrend <.001), and testing p16 IHC positive was associated with higher HPV risk group than testing p16 IHC negative for each grade of CP-diagnosed biopsies (P <.001). p16 IHC-positive, CP-diagnosed CIN2 biopsies were less likely than CP-diagnosed CIN3 biopsies to test HPV16 positive, have an antecedent HSIL+cytology, or to be diagnosed as CIN3+by the EP (P,.001 for all). p16 IHC-positive, CP-diagnosed CIN1 biopsies had lower HPV risk groups than p16 IHC-negative, CP-diagnosed CIN2 biopsies (P,.001). Conclusions.-p16 IHC-positive, CP-diagnosed CIN2 appears to be lower cancer risk than CP-diagnosed CIN3. LAST classification of "HSIL" diagnosis, which includes p16 IHC-positive CIN2, should annotate the morphologic diagnosis (CIN2 or CIN3) to inform all management decisions, which is especially important for young (<30 years) women diagnosed with CIN2 for whom surveillance rather than treatment is recommended.
UR - http://www.scopus.com/inward/record.url?scp=85083190427&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083190427&partnerID=8YFLogxK
U2 - 10.5858/arpa.2019-0241-OA
DO - 10.5858/arpa.2019-0241-OA
M3 - Article
C2 - 31718233
AN - SCOPUS:85083190427
VL - 144
SP - 725
EP - 734
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
SN - 0003-9985
IS - 6
ER -